-
The National Quality Forum (NQF), expressing its desired to reduce overcrowding and improve quality of care, has endorsed 10 national voluntary consensus standards for hospital-based ED care. The standards are:
-
Monty Gooch, RN, BSN, director of emergency services at Middle Tennessee Medical Center (MTMC) in Murfreesboro, says that one of the keys to his department's smooth patient flow door-to-doc time of 35-40 minutes despite steadily growing volume is the way it works closely with other departments.
-
Ongoing initiatives in the ED at Middle Tennessee Medical Center (MTMC) in Murfreesboro have led to improved patient flow.
-
The ED at Middle Tennessee Medical Center (MTMC) in Murfreesboro certainly qualifies as busy: it sees nearly 63,000 patients a year and averages more than 170 patients a day.
-
-
The patient whose 12-lead ECG and rhythm strip is shown above had chest discomfort at the time this tracing was recorded. In light of this history, how do you interpret the tracing?
-
Correlating the findings in the 13,331 adults 20 years or older in the Third National Health and Nutrition Examination Survey (NHANES III) revealed that vitamin D deficiency is a risk factor for developing cardiovascular disease and is associated with increased all-cause mortality.
-
Ongoing safety review of tiotropium; raloxifene reduces the risk of endometrial cancer; one-day treatment with famciclovir may be as effective as 3-day treatment with valacyclovir; new Clinical Practice Guideline from the American College of Physicians regarding pharmacologic treatment for low bone density and osteoporosis; FDA Actions.
-
Opinions on the consequences of marijuana use are wide-ranging: Some experts express grave concern that it may induce COPD, increase risk of lung cancer, promote the emergence of schizophrenia, and lead to "heavy drug" use; others essentially dismiss these (potential) adversities as inadequately established to permit accusations that marijuana has any commonplace serious adverse effects.
-
The FDA has extended the approval for the Human Papillomavirus Quadrivalent Recombinant Vaccine to include the prevention of vaginal and vulvar cancer. The vaccine, originally approved in 2006, is already approved for the prevention of cervical cancer and genital warts.
